EZH2 and neoplasm: Cytotoxicity experiments showed that the combination of DOX and EZH2 siRNA had a synergistic inhibitory effect on TNBC cells, and the nanomedicine showed excellent safety after systemic delivery due to the system’s favorable tumor-targeting ability.